Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.
The funding will be used to advance the company’s pipeline of therapies to treat degenerative eye diseases, starting with age-related macular degeneration, according to a March 25 news release from the company.
Character Biosciences has partnered with more than 150 ophthalmology treatment centers across the U.S. to conduct observational trials.
The trails integrate genetics with longitudinal clinical and imaging data from more than 6,500 patients to discover therapeutic targets to treat AMD.
In addition, the company is planning to expand and study other ophthalmic diseases in the future.
The funding was co-led by new investors aMoon and Luma Group, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
